{
  "release_id": "f6f6f1b6f50379ed",
  "id": "cardio:alirocumab",
  "owner": "cardio",
  "kind": "drug",
  "slug": "alirocumab",
  "name": "Alirocumab",
  "aliases": [
    "Praluent"
  ],
  "atlases": [
    "cardio"
  ],
  "summary_plain": "Alirocumab is an antibody, given by injection, that blocks the PCSK9 protein and lowers LDL cholesterol. In ODYSSEY OUTCOMES it lowered the rate of further heart and blood-vessel events in people after an acute coronary syndrome who took a strong statin.",
  "summary_technical": "RxNorm ingredient 1659152. Human monoclonal antibody to PCSK9 per the US drug label of Praluent (BLA125559), which is the source of the target link. A page for the branded product can be added later.",
  "editorial_state": "draft",
  "last_substantive_edit": "2026-10-15",
  "last_evidence_check": "2026-10-14",
  "next_review_due": null,
  "identifiers": [
    {
      "scheme": "rxnorm",
      "value": "1659152",
      "normalized_value": "1659152",
      "match": "exact",
      "version": null,
      "label": null,
      "from_source": false
    }
  ],
  "navigation": {
    "cardio": {
      "condition-area": [
        "coronary-and-vascular-disease"
      ]
    }
  },
  "payload": {
    "level": "substance",
    "mechanism": "Monoclonal antibody that binds PCSK9, so more LDL receptors are available to clear LDL (US drug label)"
  },
  "content_digest": "da8c21e47675583770b286a8e43fd95c80f56fed5e2f8b9180bb4facea6e0bbf",
  "review": {
    "content_digest": "da8c21e47675583770b286a8e43fd95c80f56fed5e2f8b9180bb4facea6e0bbf",
    "current": [],
    "conflicting": [],
    "stale": [],
    "inactive": []
  },
  "claims": [
    {
      "release_id": "f6f6f1b6f50379ed",
      "id": "cardio:claim-odyssey-alirocumab-after-acs",
      "owner": "cardio",
      "subject_entity_id": "cardio:alirocumab",
      "category": "effect",
      "statement": "In ODYSSEY OUTCOMES, 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier and were on high-intensity or maximum tolerated statin received alirocumab or placebo every 2 weeks. Over a median of 2.8 years, the primary composite end point occurred in 903 patients (9.5%) on alirocumab and 1052 (11.1%) on placebo (hazard ratio 0.85, 95% CI 0.78 to 0.93). Death occurred in 334 patients (3.5%) on alirocumab and 392 (4.1%) on placebo (hazard ratio 0.85, 95% CI 0.73 to 0.98). The abstract reports similar adverse events except local injection-site reactions (3.8% on alirocumab, 2.1% on placebo).",
      "context": {
        "id": "cardio:ctx-odyssey-recent-acs-on-high-intensity-statin",
        "label": "Adults 1 to 12 months after an acute coronary syndrome on high-intensity or maximum tolerated statin with raised atherogenic lipids (ODYSSEY OUTCOMES)",
        "recipient": "adult",
        "population": "Patients who had an acute coronary syndrome 1 to 12 months earlier, with LDL cholesterol of at least 70 mg/dL, non-HDL cholesterol of at least 100 mg/dL or apolipoprotein B of at least 80 mg/dL, receiving statin at a high-intensity dose or the maximum tolerated dose (abstract). The registry gives a minimum age of 40 years.",
        "care_setting": "Multicentre trial (abstract); site list not read",
        "geography": "Multinational: the study record lists every country the registry names",
        "life_stage_note": "Adult, 40 years and older (registry minimum age)",
        "life_stage_terms": null,
        "gestational_age_min_days": null,
        "gestational_age_max_days": null,
        "gestational_age_basis": null,
        "postnatal_age_min_days": null,
        "postnatal_age_max_days": null,
        "gestational_age_status": null,
        "postnatal_age_status": null,
        "followup_description": "Median follow-up 2.8 years (abstract).",
        "eligibility": {
          "inclusion": [
            "Acute coronary syndrome 1 to 12 months earlier",
            "LDL cholesterol at least 70 mg/dL, or non-HDL cholesterol at least 100 mg/dL, or apolipoprotein B at least 80 mg/dL",
            "High-intensity statin or maximum tolerated dose"
          ],
          "exclusion": []
        }
      },
      "evidence_stage": "interventional",
      "certainty": "not_assessed",
      "certainty_method": null,
      "limitations": "One randomised, double-blind trial funded by Sanofi and Regeneron according to the abstract. The abstract reports the death result as a secondary finding without saying how it was tested; this record does not claim a survival benefit beyond the numbers given. The abstract says the absolute benefit was greater in patients with baseline LDL cholesterol of 100 mg/dL or more. Abstract only.",
      "editorial_state": "draft",
      "checked_at": "2026-10-14",
      "next_review_due": null,
      "valid_from": null,
      "valid_to": null,
      "citations": [
        {
          "evidence_role": "supports",
          "locator": "Abstract, METHODS, sentence 1, fragment 1 of 5: \"We conducted a multicenter, randomized, double-blind, placebo-controlled trial involving 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier,\"",
          "applicability_note": "Abstract of the paper from PubMed; the full text was not read.",
          "snapshot": {
            "id": "cardio:pubmed-30403574-2026-10-14",
            "retrieved_at": "2026-10-14T18:18:34Z",
            "content_hash": "9e2c9d0adf253dc689cbf8a36caaf42917565582fe941874a0e1b65733c11079",
            "source_effective_date": null,
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:pubmed-10-1056-nejmoa1801174",
            "source_type": "publication",
            "title": "Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome",
            "canonical_url": "https://doi.org/10.1056/NEJMoa1801174",
            "identifiers": [
              {
                "scheme": "doi",
                "value": "10.1056/NEJMoa1801174",
                "normalized_value": "10.1056/nejmoa1801174",
                "match": "exact",
                "version": null,
                "label": null,
                "from_source": false
              },
              {
                "scheme": "pmid",
                "value": "30403574",
                "normalized_value": "30403574",
                "match": "exact",
                "version": null,
                "label": null,
                "from_source": false
              }
            ],
            "publication_date": "2018-11-29",
            "publisher": "The New England journal of medicine",
            "edition": "PubMed record (abstract and bibliographic data) from NCBI E-utilities. The full text and the version of record were not fetched.",
            "reuse_basis": "PubMed record fetched through NCBI E-utilities. Only the hash of the bytes is kept, because publisher copyright may apply to the abstract (https://pubmed.ncbi.nlm.nih.gov/disclaimer/). Short factual quotations under 25 words, with the citation.",
            "public_text": "quote"
          }
        },
        {
          "evidence_role": "supports",
          "locator": "Abstract, METHODS, sentence 1, fragment 5 of 5: \"and were receiving statin therapy at a high-intensity dose or at the maximum tolerated dose.\"",
          "applicability_note": "Statin background.",
          "snapshot": {
            "id": "cardio:pubmed-30403574-2026-10-14",
            "retrieved_at": "2026-10-14T18:18:34Z",
            "content_hash": "9e2c9d0adf253dc689cbf8a36caaf42917565582fe941874a0e1b65733c11079",
            "source_effective_date": null,
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:pubmed-10-1056-nejmoa1801174",
            "source_type": "publication",
            "title": "Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome",
            "canonical_url": "https://doi.org/10.1056/NEJMoa1801174",
            "identifiers": [
              {
                "scheme": "doi",
                "value": "10.1056/NEJMoa1801174",
                "normalized_value": "10.1056/nejmoa1801174",
                "match": "exact",
                "version": null,
                "label": null,
                "from_source": false
              },
              {
                "scheme": "pmid",
                "value": "30403574",
                "normalized_value": "30403574",
                "match": "exact",
                "version": null,
                "label": null,
                "from_source": false
              }
            ],
            "publication_date": "2018-11-29",
            "publisher": "The New England journal of medicine",
            "edition": "PubMed record (abstract and bibliographic data) from NCBI E-utilities. The full text and the version of record were not fetched.",
            "reuse_basis": "PubMed record fetched through NCBI E-utilities. Only the hash of the bytes is kept, because publisher copyright may apply to the abstract (https://pubmed.ncbi.nlm.nih.gov/disclaimer/). Short factual quotations under 25 words, with the citation.",
            "public_text": "quote"
          }
        },
        {
          "evidence_role": "supports",
          "locator": "Abstract, METHODS, sentence 2: \"Patients were randomly assigned to receive alirocumab subcutaneously at a dose of 75 mg (9462 patients) or matching placebo (9462 patients) every 2 weeks.\"",
          "applicability_note": "Dose and schedule of alirocumab and placebo.",
          "snapshot": {
            "id": "cardio:pubmed-30403574-2026-10-14",
            "retrieved_at": "2026-10-14T18:18:34Z",
            "content_hash": "9e2c9d0adf253dc689cbf8a36caaf42917565582fe941874a0e1b65733c11079",
            "source_effective_date": null,
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:pubmed-10-1056-nejmoa1801174",
            "source_type": "publication",
            "title": "Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome",
            "canonical_url": "https://doi.org/10.1056/NEJMoa1801174",
            "identifiers": [
              {
                "scheme": "doi",
                "value": "10.1056/NEJMoa1801174",
                "normalized_value": "10.1056/nejmoa1801174",
                "match": "exact",
                "version": null,
                "label": null,
                "from_source": false
              },
              {
                "scheme": "pmid",
                "value": "30403574",
                "normalized_value": "30403574",
                "match": "exact",
                "version": null,
                "label": null,
                "from_source": false
              }
            ],
            "publication_date": "2018-11-29",
            "publisher": "The New England journal of medicine",
            "edition": "PubMed record (abstract and bibliographic data) from NCBI E-utilities. The full text and the version of record were not fetched.",
            "reuse_basis": "PubMed record fetched through NCBI E-utilities. Only the hash of the bytes is kept, because publisher copyright may apply to the abstract (https://pubmed.ncbi.nlm.nih.gov/disclaimer/). Short factual quotations under 25 words, with the citation.",
            "public_text": "quote"
          }
        },
        {
          "evidence_role": "supports",
          "locator": "Abstract, METHODS, sentence 4, fragment 1 of 2: \"The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke,\"",
          "applicability_note": "Primary end point, first part.",
          "snapshot": {
            "id": "cardio:pubmed-30403574-2026-10-14",
            "retrieved_at": "2026-10-14T18:18:34Z",
            "content_hash": "9e2c9d0adf253dc689cbf8a36caaf42917565582fe941874a0e1b65733c11079",
            "source_effective_date": null,
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:pubmed-10-1056-nejmoa1801174",
            "source_type": "publication",
            "title": "Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome",
            "canonical_url": "https://doi.org/10.1056/NEJMoa1801174",
            "identifiers": [
              {
                "scheme": "doi",
                "value": "10.1056/NEJMoa1801174",
                "normalized_value": "10.1056/nejmoa1801174",
                "match": "exact",
                "version": null,
                "label": null,
                "from_source": false
              },
              {
                "scheme": "pmid",
                "value": "30403574",
                "normalized_value": "30403574",
                "match": "exact",
                "version": null,
                "label": null,
                "from_source": false
              }
            ],
            "publication_date": "2018-11-29",
            "publisher": "The New England journal of medicine",
            "edition": "PubMed record (abstract and bibliographic data) from NCBI E-utilities. The full text and the version of record were not fetched.",
            "reuse_basis": "PubMed record fetched through NCBI E-utilities. Only the hash of the bytes is kept, because publisher copyright may apply to the abstract (https://pubmed.ncbi.nlm.nih.gov/disclaimer/). Short factual quotations under 25 words, with the citation.",
            "public_text": "quote"
          }
        },
        {
          "evidence_role": "supports",
          "locator": "Abstract, METHODS, sentence 4, fragment 2 of 2: \"or unstable angina requiring hospitalization.\"",
          "applicability_note": "Primary end point, last part.",
          "snapshot": {
            "id": "cardio:pubmed-30403574-2026-10-14",
            "retrieved_at": "2026-10-14T18:18:34Z",
            "content_hash": "9e2c9d0adf253dc689cbf8a36caaf42917565582fe941874a0e1b65733c11079",
            "source_effective_date": null,
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:pubmed-10-1056-nejmoa1801174",
            "source_type": "publication",
            "title": "Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome",
            "canonical_url": "https://doi.org/10.1056/NEJMoa1801174",
            "identifiers": [
              {
                "scheme": "doi",
                "value": "10.1056/NEJMoa1801174",
                "normalized_value": "10.1056/nejmoa1801174",
                "match": "exact",
                "version": null,
                "label": null,
                "from_source": false
              },
              {
                "scheme": "pmid",
                "value": "30403574",
                "normalized_value": "30403574",
                "match": "exact",
                "version": null,
                "label": null,
                "from_source": false
              }
            ],
            "publication_date": "2018-11-29",
            "publisher": "The New England journal of medicine",
            "edition": "PubMed record (abstract and bibliographic data) from NCBI E-utilities. The full text and the version of record were not fetched.",
            "reuse_basis": "PubMed record fetched through NCBI E-utilities. Only the hash of the bytes is kept, because publisher copyright may apply to the abstract (https://pubmed.ncbi.nlm.nih.gov/disclaimer/). Short factual quotations under 25 words, with the citation.",
            "public_text": "quote"
          }
        },
        {
          "evidence_role": "supports",
          "locator": "Abstract, RESULTS, sentence 1: \"The median duration of follow-up was 2.8 years.\"",
          "applicability_note": "Median follow-up.",
          "snapshot": {
            "id": "cardio:pubmed-30403574-2026-10-14",
            "retrieved_at": "2026-10-14T18:18:34Z",
            "content_hash": "9e2c9d0adf253dc689cbf8a36caaf42917565582fe941874a0e1b65733c11079",
            "source_effective_date": null,
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:pubmed-10-1056-nejmoa1801174",
            "source_type": "publication",
            "title": "Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome",
            "canonical_url": "https://doi.org/10.1056/NEJMoa1801174",
            "identifiers": [
              {
                "scheme": "doi",
                "value": "10.1056/NEJMoa1801174",
                "normalized_value": "10.1056/nejmoa1801174",
                "match": "exact",
                "version": null,
                "label": null,
                "from_source": false
              },
              {
                "scheme": "pmid",
                "value": "30403574",
                "normalized_value": "30403574",
                "match": "exact",
                "version": null,
                "label": null,
                "from_source": false
              }
            ],
            "publication_date": "2018-11-29",
            "publisher": "The New England journal of medicine",
            "edition": "PubMed record (abstract and bibliographic data) from NCBI E-utilities. The full text and the version of record were not fetched.",
            "reuse_basis": "PubMed record fetched through NCBI E-utilities. Only the hash of the bytes is kept, because publisher copyright may apply to the abstract (https://pubmed.ncbi.nlm.nih.gov/disclaimer/). Short factual quotations under 25 words, with the citation.",
            "public_text": "quote"
          }
        },
        {
          "evidence_role": "supports",
          "locator": "Abstract, RESULTS, sentence 2, fragment 1 of 2: \"A composite primary end-point event occurred in 903 patients (9.5%) in the alirocumab group and in 1052 patients (11.1%)\"",
          "applicability_note": "Primary end point counts.",
          "snapshot": {
            "id": "cardio:pubmed-30403574-2026-10-14",
            "retrieved_at": "2026-10-14T18:18:34Z",
            "content_hash": "9e2c9d0adf253dc689cbf8a36caaf42917565582fe941874a0e1b65733c11079",
            "source_effective_date": null,
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:pubmed-10-1056-nejmoa1801174",
            "source_type": "publication",
            "title": "Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome",
            "canonical_url": "https://doi.org/10.1056/NEJMoa1801174",
            "identifiers": [
              {
                "scheme": "doi",
                "value": "10.1056/NEJMoa1801174",
                "normalized_value": "10.1056/nejmoa1801174",
                "match": "exact",
                "version": null,
                "label": null,
                "from_source": false
              },
              {
                "scheme": "pmid",
                "value": "30403574",
                "normalized_value": "30403574",
                "match": "exact",
                "version": null,
                "label": null,
                "from_source": false
              }
            ],
            "publication_date": "2018-11-29",
            "publisher": "The New England journal of medicine",
            "edition": "PubMed record (abstract and bibliographic data) from NCBI E-utilities. The full text and the version of record were not fetched.",
            "reuse_basis": "PubMed record fetched through NCBI E-utilities. Only the hash of the bytes is kept, because publisher copyright may apply to the abstract (https://pubmed.ncbi.nlm.nih.gov/disclaimer/). Short factual quotations under 25 words, with the citation.",
            "public_text": "quote"
          }
        },
        {
          "evidence_role": "supports",
          "locator": "Abstract, RESULTS, sentence 2, fragment 2 of 2: \"in the placebo group (hazard ratio, 0.85; 95% confidence interval [CI], 0.78 to 0.93; P<0.001).\"",
          "applicability_note": "Primary end point hazard ratio.",
          "snapshot": {
            "id": "cardio:pubmed-30403574-2026-10-14",
            "retrieved_at": "2026-10-14T18:18:34Z",
            "content_hash": "9e2c9d0adf253dc689cbf8a36caaf42917565582fe941874a0e1b65733c11079",
            "source_effective_date": null,
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:pubmed-10-1056-nejmoa1801174",
            "source_type": "publication",
            "title": "Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome",
            "canonical_url": "https://doi.org/10.1056/NEJMoa1801174",
            "identifiers": [
              {
                "scheme": "doi",
                "value": "10.1056/NEJMoa1801174",
                "normalized_value": "10.1056/nejmoa1801174",
                "match": "exact",
                "version": null,
                "label": null,
                "from_source": false
              },
              {
                "scheme": "pmid",
                "value": "30403574",
                "normalized_value": "30403574",
                "match": "exact",
                "version": null,
                "label": null,
                "from_source": false
              }
            ],
            "publication_date": "2018-11-29",
            "publisher": "The New England journal of medicine",
            "edition": "PubMed record (abstract and bibliographic data) from NCBI E-utilities. The full text and the version of record were not fetched.",
            "reuse_basis": "PubMed record fetched through NCBI E-utilities. Only the hash of the bytes is kept, because publisher copyright may apply to the abstract (https://pubmed.ncbi.nlm.nih.gov/disclaimer/). Short factual quotations under 25 words, with the citation.",
            "public_text": "quote"
          }
        },
        {
          "evidence_role": "supports",
          "locator": "Abstract, RESULTS, sentence 3, fragment 1 of 2: \"A total of 334 patients (3.5%) in the alirocumab group and 392 patients (4.1%) in the placebo group died (hazard ratio, 0.85; 95% CI,\"",
          "applicability_note": "Deaths, counts and hazard ratio.",
          "snapshot": {
            "id": "cardio:pubmed-30403574-2026-10-14",
            "retrieved_at": "2026-10-14T18:18:34Z",
            "content_hash": "9e2c9d0adf253dc689cbf8a36caaf42917565582fe941874a0e1b65733c11079",
            "source_effective_date": null,
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:pubmed-10-1056-nejmoa1801174",
            "source_type": "publication",
            "title": "Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome",
            "canonical_url": "https://doi.org/10.1056/NEJMoa1801174",
            "identifiers": [
              {
                "scheme": "doi",
                "value": "10.1056/NEJMoa1801174",
                "normalized_value": "10.1056/nejmoa1801174",
                "match": "exact",
                "version": null,
                "label": null,
                "from_source": false
              },
              {
                "scheme": "pmid",
                "value": "30403574",
                "normalized_value": "30403574",
                "match": "exact",
                "version": null,
                "label": null,
                "from_source": false
              }
            ],
            "publication_date": "2018-11-29",
            "publisher": "The New England journal of medicine",
            "edition": "PubMed record (abstract and bibliographic data) from NCBI E-utilities. The full text and the version of record were not fetched.",
            "reuse_basis": "PubMed record fetched through NCBI E-utilities. Only the hash of the bytes is kept, because publisher copyright may apply to the abstract (https://pubmed.ncbi.nlm.nih.gov/disclaimer/). Short factual quotations under 25 words, with the citation.",
            "public_text": "quote"
          }
        },
        {
          "evidence_role": "supports",
          "locator": "Abstract, RESULTS, sentence 3, fragment 2 of 2: \"0.73 to 0.98).\"",
          "applicability_note": "Deaths, interval.",
          "snapshot": {
            "id": "cardio:pubmed-30403574-2026-10-14",
            "retrieved_at": "2026-10-14T18:18:34Z",
            "content_hash": "9e2c9d0adf253dc689cbf8a36caaf42917565582fe941874a0e1b65733c11079",
            "source_effective_date": null,
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:pubmed-10-1056-nejmoa1801174",
            "source_type": "publication",
            "title": "Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome",
            "canonical_url": "https://doi.org/10.1056/NEJMoa1801174",
            "identifiers": [
              {
                "scheme": "doi",
                "value": "10.1056/NEJMoa1801174",
                "normalized_value": "10.1056/nejmoa1801174",
                "match": "exact",
                "version": null,
                "label": null,
                "from_source": false
              },
              {
                "scheme": "pmid",
                "value": "30403574",
                "normalized_value": "30403574",
                "match": "exact",
                "version": null,
                "label": null,
                "from_source": false
              }
            ],
            "publication_date": "2018-11-29",
            "publisher": "The New England journal of medicine",
            "edition": "PubMed record (abstract and bibliographic data) from NCBI E-utilities. The full text and the version of record were not fetched.",
            "reuse_basis": "PubMed record fetched through NCBI E-utilities. Only the hash of the bytes is kept, because publisher copyright may apply to the abstract (https://pubmed.ncbi.nlm.nih.gov/disclaimer/). Short factual quotations under 25 words, with the citation.",
            "public_text": "quote"
          }
        },
        {
          "evidence_role": "supports",
          "locator": "Abstract, RESULTS, sentence 4, fragment 1 of 2: \"The absolute benefit of alirocumab with respect to the composite primary end point was greater among patients who had a baseline LDL cholesterol level\"",
          "applicability_note": "Baseline LDL subgroup.",
          "snapshot": {
            "id": "cardio:pubmed-30403574-2026-10-14",
            "retrieved_at": "2026-10-14T18:18:34Z",
            "content_hash": "9e2c9d0adf253dc689cbf8a36caaf42917565582fe941874a0e1b65733c11079",
            "source_effective_date": null,
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:pubmed-10-1056-nejmoa1801174",
            "source_type": "publication",
            "title": "Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome",
            "canonical_url": "https://doi.org/10.1056/NEJMoa1801174",
            "identifiers": [
              {
                "scheme": "doi",
                "value": "10.1056/NEJMoa1801174",
                "normalized_value": "10.1056/nejmoa1801174",
                "match": "exact",
                "version": null,
                "label": null,
                "from_source": false
              },
              {
                "scheme": "pmid",
                "value": "30403574",
                "normalized_value": "30403574",
                "match": "exact",
                "version": null,
                "label": null,
                "from_source": false
              }
            ],
            "publication_date": "2018-11-29",
            "publisher": "The New England journal of medicine",
            "edition": "PubMed record (abstract and bibliographic data) from NCBI E-utilities. The full text and the version of record were not fetched.",
            "reuse_basis": "PubMed record fetched through NCBI E-utilities. Only the hash of the bytes is kept, because publisher copyright may apply to the abstract (https://pubmed.ncbi.nlm.nih.gov/disclaimer/). Short factual quotations under 25 words, with the citation.",
            "public_text": "quote"
          }
        },
        {
          "evidence_role": "supports",
          "locator": "Abstract, RESULTS, sentence 4, fragment 2 of 2: \"of 100 mg or more per deciliter than among patients who had a lower baseline level.\"",
          "applicability_note": "Baseline LDL subgroup, threshold.",
          "snapshot": {
            "id": "cardio:pubmed-30403574-2026-10-14",
            "retrieved_at": "2026-10-14T18:18:34Z",
            "content_hash": "9e2c9d0adf253dc689cbf8a36caaf42917565582fe941874a0e1b65733c11079",
            "source_effective_date": null,
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:pubmed-10-1056-nejmoa1801174",
            "source_type": "publication",
            "title": "Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome",
            "canonical_url": "https://doi.org/10.1056/NEJMoa1801174",
            "identifiers": [
              {
                "scheme": "doi",
                "value": "10.1056/NEJMoa1801174",
                "normalized_value": "10.1056/nejmoa1801174",
                "match": "exact",
                "version": null,
                "label": null,
                "from_source": false
              },
              {
                "scheme": "pmid",
                "value": "30403574",
                "normalized_value": "30403574",
                "match": "exact",
                "version": null,
                "label": null,
                "from_source": false
              }
            ],
            "publication_date": "2018-11-29",
            "publisher": "The New England journal of medicine",
            "edition": "PubMed record (abstract and bibliographic data) from NCBI E-utilities. The full text and the version of record were not fetched.",
            "reuse_basis": "PubMed record fetched through NCBI E-utilities. Only the hash of the bytes is kept, because publisher copyright may apply to the abstract (https://pubmed.ncbi.nlm.nih.gov/disclaimer/). Short factual quotations under 25 words, with the citation.",
            "public_text": "quote"
          }
        },
        {
          "evidence_role": "supports",
          "locator": "Abstract, RESULTS, sentence 5, fragment 1 of 2: \"The incidence of adverse events was similar in the two groups, with the exception of local injection-site reactions (3.8% in the alirocumab group vs.\"",
          "applicability_note": "Adverse events.",
          "snapshot": {
            "id": "cardio:pubmed-30403574-2026-10-14",
            "retrieved_at": "2026-10-14T18:18:34Z",
            "content_hash": "9e2c9d0adf253dc689cbf8a36caaf42917565582fe941874a0e1b65733c11079",
            "source_effective_date": null,
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:pubmed-10-1056-nejmoa1801174",
            "source_type": "publication",
            "title": "Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome",
            "canonical_url": "https://doi.org/10.1056/NEJMoa1801174",
            "identifiers": [
              {
                "scheme": "doi",
                "value": "10.1056/NEJMoa1801174",
                "normalized_value": "10.1056/nejmoa1801174",
                "match": "exact",
                "version": null,
                "label": null,
                "from_source": false
              },
              {
                "scheme": "pmid",
                "value": "30403574",
                "normalized_value": "30403574",
                "match": "exact",
                "version": null,
                "label": null,
                "from_source": false
              }
            ],
            "publication_date": "2018-11-29",
            "publisher": "The New England journal of medicine",
            "edition": "PubMed record (abstract and bibliographic data) from NCBI E-utilities. The full text and the version of record were not fetched.",
            "reuse_basis": "PubMed record fetched through NCBI E-utilities. Only the hash of the bytes is kept, because publisher copyright may apply to the abstract (https://pubmed.ncbi.nlm.nih.gov/disclaimer/). Short factual quotations under 25 words, with the citation.",
            "public_text": "quote"
          }
        },
        {
          "evidence_role": "supports",
          "locator": "Abstract, RESULTS, sentence 5, fragment 2 of 2: \"2.1% in the placebo group).\"",
          "applicability_note": "Injection-site reactions, placebo.",
          "snapshot": {
            "id": "cardio:pubmed-30403574-2026-10-14",
            "retrieved_at": "2026-10-14T18:18:34Z",
            "content_hash": "9e2c9d0adf253dc689cbf8a36caaf42917565582fe941874a0e1b65733c11079",
            "source_effective_date": null,
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:pubmed-10-1056-nejmoa1801174",
            "source_type": "publication",
            "title": "Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome",
            "canonical_url": "https://doi.org/10.1056/NEJMoa1801174",
            "identifiers": [
              {
                "scheme": "doi",
                "value": "10.1056/NEJMoa1801174",
                "normalized_value": "10.1056/nejmoa1801174",
                "match": "exact",
                "version": null,
                "label": null,
                "from_source": false
              },
              {
                "scheme": "pmid",
                "value": "30403574",
                "normalized_value": "30403574",
                "match": "exact",
                "version": null,
                "label": null,
                "from_source": false
              }
            ],
            "publication_date": "2018-11-29",
            "publisher": "The New England journal of medicine",
            "edition": "PubMed record (abstract and bibliographic data) from NCBI E-utilities. The full text and the version of record were not fetched.",
            "reuse_basis": "PubMed record fetched through NCBI E-utilities. Only the hash of the bytes is kept, because publisher copyright may apply to the abstract (https://pubmed.ncbi.nlm.nih.gov/disclaimer/). Short factual quotations under 25 words, with the citation.",
            "public_text": "quote"
          }
        },
        {
          "evidence_role": "context",
          "locator": "Abstract, CONCLUSIONS, sentence 2: \"(Funded by Sanofi and Regeneron Pharmaceuticals; ODYSSEY OUTCOMES ClinicalTrials.gov number, NCT01663402 .).\"",
          "applicability_note": "Funding note in the abstract.",
          "snapshot": {
            "id": "cardio:pubmed-30403574-2026-10-14",
            "retrieved_at": "2026-10-14T18:18:34Z",
            "content_hash": "9e2c9d0adf253dc689cbf8a36caaf42917565582fe941874a0e1b65733c11079",
            "source_effective_date": null,
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:pubmed-10-1056-nejmoa1801174",
            "source_type": "publication",
            "title": "Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome",
            "canonical_url": "https://doi.org/10.1056/NEJMoa1801174",
            "identifiers": [
              {
                "scheme": "doi",
                "value": "10.1056/NEJMoa1801174",
                "normalized_value": "10.1056/nejmoa1801174",
                "match": "exact",
                "version": null,
                "label": null,
                "from_source": false
              },
              {
                "scheme": "pmid",
                "value": "30403574",
                "normalized_value": "30403574",
                "match": "exact",
                "version": null,
                "label": null,
                "from_source": false
              }
            ],
            "publication_date": "2018-11-29",
            "publisher": "The New England journal of medicine",
            "edition": "PubMed record (abstract and bibliographic data) from NCBI E-utilities. The full text and the version of record were not fetched.",
            "reuse_basis": "PubMed record fetched through NCBI E-utilities. Only the hash of the bytes is kept, because publisher copyright may apply to the abstract (https://pubmed.ncbi.nlm.nih.gov/disclaimer/). Short factual quotations under 25 words, with the citation.",
            "public_text": "quote"
          }
        }
      ],
      "review": {
        "content_digest": "dbccf6e9c152a954eb41e5186d531800312e0ff424e2fb009495a64ad83d0dcc",
        "current": [],
        "conflicting": [],
        "stale": [],
        "inactive": []
      },
      "api_path": "api/v1/claims/cardio--claim-odyssey-alirocumab-after-acs.json"
    }
  ],
  "decisions": [],
  "milestones": [],
  "relationships": {
    "outgoing": [
      {
        "predicate": "evaluated_for",
        "label": "Fewer events after acute coronary syndrome",
        "clinical_claim_not_fact": true,
        "family": "clinical",
        "other_entity_id": "cardio:coronary-artery-disease",
        "other_entity_in_atlas": true,
        "claim_id": "cardio:claim-odyssey-alirocumab-after-acs",
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "targets",
        "label": "Binds PCSK9",
        "clinical_claim_not_fact": false,
        "family": "sourced",
        "other_entity_id": "cardio:pcsk9",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": {
          "snapshot_id": "cardio:openfda-label-446f6b5c-0dd4-44ff-9bc2-c2b41f2806b4-2026-10-14",
          "locator": "results[0].mechanism_of_action[0]"
        },
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "part_of",
        "label": "Files under this front",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:front-medicines",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      }
    ],
    "incoming": [
      {
        "predicate": "investigates",
        "label": "Investigated in",
        "clinical_claim_not_fact": false,
        "family": "sourced",
        "other_entity_id": "cardio:odyssey-outcomes",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": {
          "snapshot_id": "cardio:ctgov-nct01663402-2026-10-14",
          "locator": "protocolSection.armsInterventionsModule.interventions[0].name"
        },
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      }
    ]
  },
  "page_path": "drugs/alirocumab/",
  "context_path": "api/v1/context/cardio--alirocumab.md"
}